Clinical Trials

1,301 enrolled 16 charts

Melanoma

NCT04079712 2026-03-18

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT03799445 2026-03-17

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

37 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

50 enrolled 12 charts

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

71 enrolled 9 charts

Melanoma

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT04396860 2026-03-05

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Sarcoma

Gliosarcoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Melanoma

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

281 enrolled 44 charts

Melanoma, Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

17 enrolled 8 charts

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT03143153 2026-02-17

CheckMate 648

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT03203473 2026-02-06

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

85 enrolled 17 charts

Kidney Neoplasms

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

30 enrolled 15 charts

Breast

Breast Neoplasms

NCT02919683 2026-01-28

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

30 enrolled 14 charts

Head and Neck Neoplasms

NCT02648997 2026-01-26

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Phase 1/2 Active not recruiting

40 enrolled 14 charts

CNS

Meningioma

NCT03377023 2026-01-22

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

66 enrolled 17 charts

GastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung

NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

79 enrolled 24 charts

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

NCT03285321 2026-01-20

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

105 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03575793 2026-01-20

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

39 enrolled 18 charts

Lung Neoplasms

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03425331 2026-01-08

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Phase 2 Terminated

5 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

20 enrolled 13 charts

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

11 enrolled 11 charts

Melanoma

NCT01658878 2025-12-24

CheckMate040

657 enrolled 57 charts 3 FDA

Carcinoma, Hepatocellular

NCT02985957 2025-12-22

CheckMate 650

351 enrolled 43 charts

Prostatic Neoplasms

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT03172624 2025-12-18

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

64 enrolled 9 charts

Salivary Gland Neoplasms

NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Phase 1 Completed

31 enrolled 20 charts

Other solid neoplasm

Metastatic Solid Tumors

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT01950390 2025-12-11

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

169 enrolled 14 charts

Melanoma

NCT02259621 2025-12-03

NA_00092076

39 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT03377361 2025-12-03

CheckMate 9N9

325 enrolled 31 charts

Colorectal Neoplasms

NCT04021043 2025-12-03

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

51 enrolled 16 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT01708941 2025-11-26

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

88 enrolled 14 charts

Melanoma

NCT03369223 2025-11-18

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

356 enrolled 43 charts

Advanced Cancer

NCT02939300 2025-11-14

Ipilimumab and Nivolumab in Leptomeningeal Metastases

18 enrolled 17 charts

CNS

Meningeal Carcinomatosis

NCT02060188 2025-11-06

CheckMate142

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03573947 2025-10-14

TOP1705

46 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03404960 2025-10-10

Parpvax

104 enrolled 11 charts

Pancreatic Adenocarcinoma

NCT04008030 2025-10-03

CheckMate 8HW

839 enrolled 22 charts 1 FDA

Colorectal Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

68 enrolled 27 charts

Tumor-Agnostic

Neoplasms

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

37 enrolled 32 charts

Other solid neoplasm

Solid Tumor

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT02498600 2025-08-29

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer